Effect of Hataedock Treatment on Epidermal Structure Maintenance through Intervention in the Endocannabinoid System
Laboratory studyOther animalsWith Douchi (fermented soybean) extract used as Hataedock; genistein and PEA compared in a separate involucrin assay
This study tested palmitoylethanolamide together with Douchi (fermented soybean) extract used as Hataedock; genistein and PEA compared in a separate involucrin assay. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- NC/Nga mice with Dermatophagoides farinae-induced atopic dermatitis (numbers not stated in the abstract)
- Dose used in the study
- Douchi extract 20 mg/kg by mouth; PEA used in an involucrin expression test, concentration not stated
- Duration
- Mite extract applied in weeks 4 to 6 and 8 to 10
- What was measured
- Clinical scores, skin histology, CB1, CB2 and GPR55 expression, barrier proteins (filaggrin, involucrin, loricrin, Lass2), E-cadherin, GPx4, CD1A, apoptosis, p-ERK, p-JNK, p-mTOR and epidermal thickness; involucrin after genistein or PEA.
What the authors reported
Hataedock treatment reduced clinical scores (p<0.01) and histological signs, raised cannabinoid receptor and barrier protein expression, raised E-cadherin and GPx4, lowered CD1A, and reduced p-ERK, p-JNK, p-mTOR and epidermal thickness. In the involucrin test, genistein produced a greater lipid barrier effect than PEA.
Limits of this study
A mouse model of atopic dermatitis testing a fermented soybean preparation; PEA was only a comparator in one assay and performed less well than genistein. It cannot show effect in people. The authors declare no conflicts of interest.
Source
PubMed 32063982 · doi:10.1155/2020/3605153
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.